Prelude Therapeutics Incorporated PRLD Stock
Prelude Therapeutics Incorporated Price Chart
Prelude Therapeutics Incorporated PRLD Financial and Trading Overview
| Prelude Therapeutics Incorporated stock price | 5.62 USD |
| Previous Close | 5.35 USD |
| Open | 5.28 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 1100 |
| Day's Range | 5.08 - 5.4 USD |
| 52 Week Range | 4.33 - 8.9 USD |
| Volume | 56.1K USD |
| Avg. Volume | 107.33K USD |
| Market Cap | 277.47M USD |
| Beta (5Y Monthly) | 0.470124 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.02 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.75 USD |
PRLD Valuation Measures
| Enterprise Value | 84.99M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.5931373 |
| PEG Ratio (5 yr expected) | -0.07 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.4422028 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.702 |
Trading Information
Prelude Therapeutics Incorporated Stock Price History
| Beta (5Y Monthly) | 0.470124 |
| 52-Week Change | 11.60% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 8.9 USD |
| 52 Week Low | 4.33 USD |
| 50-Day Moving Average | 6.18 USD |
| 200-Day Moving Average | 6.34 USD |
PRLD Share Statistics
| Avg. Volume (3 month) | 107.33K USD |
| Avg. Daily Volume (10-Days) | 72.11K USD |
| Shares Outstanding | 39.6M |
| Float | 20.58M |
| Short Ratio | 20.19 |
| % Held by Insiders | 7.43% |
| % Held by Institutions | 77.17% |
| Shares Short | 2.55M |
| Short % of Float | 23.53% |
| Short % of Shares Outstanding | 4.86% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.93% |
| Return on Equity (ttm) | -52.019% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -121072000 USD |
| Net Income Avi to Common (ttm) | -113691000 USD |
| Diluted EPS (ttm) | -2.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 172.26M USD |
| Total Cash Per Share (mrq) | 3.6 USD |
| Total Debt (mrq) | 1.39M USD |
| Total Debt/Equity (mrq) | 0.79 USD |
| Current Ratio (mrq) | 8.914 |
| Book Value Per Share (mrq) | 3.668 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -91968000 USD |
| Levered Free Cash Flow (ttm) | -48653376 USD |
Profile of Prelude Therapeutics Incorporated
| Country | United States |
| State | DE |
| City | Wilmington |
| Address | 200 Powder Mill Road |
| ZIP | 19803 |
| Phone | (302) 467-1280 |
| Website | https://preludetx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 122 |
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Q&A For Prelude Therapeutics Incorporated Stock
What is a current PRLD stock price?
Prelude Therapeutics Incorporated PRLD stock price today per share is 5.62 USD.
How to purchase Prelude Therapeutics Incorporated stock?
You can buy PRLD shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Prelude Therapeutics Incorporated?
The stock symbol or ticker of Prelude Therapeutics Incorporated is PRLD.
Which industry does the Prelude Therapeutics Incorporated company belong to?
The Prelude Therapeutics Incorporated industry is Biotechnology.
How many shares does Prelude Therapeutics Incorporated have in circulation?
The max supply of Prelude Therapeutics Incorporated shares is 54.92M.
What is Prelude Therapeutics Incorporated Price to Earnings Ratio (PE Ratio)?
Prelude Therapeutics Incorporated PE Ratio is now.
What was Prelude Therapeutics Incorporated earnings per share over the trailing 12 months (TTM)?
Prelude Therapeutics Incorporated EPS is -2.02 USD over the trailing 12 months.
Which sector does the Prelude Therapeutics Incorporated company belong to?
The Prelude Therapeutics Incorporated sector is Healthcare.
Prelude Therapeutics Incorporated PRLD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}